Pituitary responses to a dopamine antagonist at different times of the day in normal women

1982 ◽  
Vol 100 (4) ◽  
pp. 481-485 ◽  
Author(s):  
F. R. Pérez-López ◽  
C. M. González-Moreno ◽  
M. D. Abós ◽  
J. A. Andonegui ◽  
R. H. Corvo
Keyword(s):  
Serum Prolactin ◽  
Dopamine Antagonist ◽  
Hormonal Changes ◽  
Healthy Women ◽  
Serum Lh ◽  
Normal Women ◽  
The Times ◽  
Serum Tsh

Abstract. In order to determine whether or not pituitary responsiveness to the dopaminergic antagonist clebopride changes during the nyctohemeral cycle, 10 healthy women with regular cycles were given 1 mg of clebopride orally at 09.00 h and 24.00 h with at least a 5 day interval between each test. In addition, 5 of the women were given a placebo instead of clebopride at midnight to evaluate the spontaneous hormonal changes. During the 24.00 h test the women had significantly higher P < 0.05) mean TSH basal levels. Serum prolactin (Prl) increased significantly (P < 0.001) after clebopride administration while these changes did not occur when placebo was used instead of clebopride at midnight. The Prl response to clebopride was qualitatively similar at 09.00 h and at 24.00 h. Clebopride given at midnight induced a significant increase (P < 0.05) in serum TSH while this change did not occur when the drug was given at 09.00 h or when placebo was given at midnight. The administration of clebopride resulted in no discernible alterations in serum LH, FSH or GH in either the 09.00 h or the 24.00 h tests. Thus, Prl responses to clebopride were similar in the morning and at midnight, TSH significantly increased after clebopride at midnight whereas this did not occur when the drug was given in the morning, and no significant changes were induced in LH, FSH or GH at the times studied.

THE SEQUENCE OF HORMONAL CHANGES DURING PROSTAGLANDIN INDUCED LUTEOLYSIS OF THE SUPERLUTEINIZED RAT OVARY

1978 ◽  
Vol 87 (3) ◽  
pp. 617-624 ◽  
Author(s):  
P. A. Torjesen ◽  
R. Dahlin ◽  
E. Haug ◽  
A. Aakvaag
Keyword(s):  
Binding Sites ◽  
Limit Of Detection ◽  
Serum Levels ◽  
Female Rats ◽  
Serum Prolactin ◽  
Hormonal Changes ◽  
Subsequent Increase ◽  
Serum Progesterone ◽  
Serum Lh ◽  
Prostaglandin F

ABSTRACT Immature female rats were pre-treated with pregnant mare's serum gonadotrophin (PMSG) and human chorionic gonadotrophin (HCG) to achieve superluteinization. Eight days after the HCG administration luteolysis was induced by sc injection of 5 μg of the prostaglandin F2α (PGF2α) analogue cloprostenol (Estrumate®). The serum levels of progesterone, 20α-dihydroprogesterone (20α-DHP), prolactin (PRL) and luteinizing hormone (LH) as well as the number of ovarian LH binding sites were measured during the first 23 h after cloprostenol injection. The serum levels of progesterone decreased from 500 to 200 ng/ml within 25 min after cloprostenol administration. A further decrease to 20 ng/ml occurred during the next 4 h, and serum progesterone remained low for the rest of the period. An increase in serum prolactin (PRL) to values between 28 and 44 ng/ml was observed after 3 h and the values remained elevated for the next 7 h. Although the serum levels of progesterone declined immediately, the serum 20α-dihydroprogesterone (20α-DHP) levels remained at 60 to 140 ng/ml for the first 5 h and then gradually increased to values corresponding to the initial progesterone levels 14 to 23 h after treatment. The number of ovarian LH binding sites was between 1.2 and 1.4 × 10−12 mol/mg protein during the first 9 h after prostaglandin (PG) injection, and then decrreased to 0.8 and 0.5 × 10−12 mol/mg protein at 14 and 23 h, respectively. The serum LH levels remained below the limit of detection for the assay (10 ng/ml) throughout the observation period. PGF2α injection induced the same basic changes in the serum levels of progesterone and 20α-DHP as cloprostenol treatment. Thus, the first effect of PG treatment measured was an immediate decline in the serum levels of progesterone, and this decline probably initiated the subsequent increase in pituitay PRL and ovarian 20α-DHP secretion. Therefore, the decrease in the number of ovarian LH binding sites appeared to be a consequence rather than a mediator of luteolytic effects of the prostaglandins.

scholarly journals A Study on Subfertile Women Suffering from Polycystic Ovarian Syndrome with Hyperprolactinaemia and Hypothyroidism as Associated Factors

2014 ◽  
Vol 31 (3) ◽  
pp. 140-143
Author(s):  
SA Anwary ◽  
S Chowdhury ◽  
P Fatima ◽  
M Alfazzaman ◽  
N Begum ◽  
...  
Keyword(s):  
Subclinical Hypothyroidism ◽  
Associated Factors ◽  
Polycystic Ovarian Syndrome ◽  
Serum Prolactin ◽  
Lower Abdomen ◽  
Obstetrics And Gynaecology ◽  
Serum Lh ◽  
Medical University ◽  
Ovarian Syndrome ◽  
Serum Tsh

Objective: This study tried to evaluate association of other factors of subfertility in women suffering from polycystic ovarian syndrome (PCOS). Methods: Fifty subfertile women suffering from PCOS attending infertility unit of the Department of Obstetrics and Gynaecology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, during July 2010 and June 2011, were evaluated. Results: In out study, Age, BMI and duration of marriage range was 20 38 years, 17.70 33.20 kg/m2 and 1 16 years, respectively. Serum FSH was normal (1.0 10.0 mIU/ml) in all 50 (100%) women. Hyperprolactinaemia (serum prolactin >25 ng/ml) was seen in 60%. Hypothyroidism (serum TSH >4 ìIU/ml) was seen in 74% women. Serum LH (>10 mIU/ml) was raised in 74%. USG finding of lower abdomen was abnormal in 75% cases. Conclusion: This study concludes that hyperprolactinaemia and subclinical hypothyroidism were associated causes of subfertility other than PCOS. DOI: http://dx.doi.org/10.3329/jbcps.v31i3.20980 J Bangladesh Coll Phys Surg 2013; 31: 140-143

The effects of dopaminergic blockade on serum TSH and prolactin levels in thyrotoxicosis

1984 ◽  
Vol 106 (3) ◽  
pp. 330-335 ◽  
Author(s):  
S. Swart ◽  
B. P. O'Malley ◽  
J. Vora ◽  
D. B. Barnett ◽  
F. D. Rosenthal
Keyword(s):  
Significant Decline ◽  
Serum Prolactin ◽  
Control Group ◽  
Dopamine Antagonist ◽  
Serum Samples ◽  
Before And After ◽  
Dopaminergic Tone ◽  
Long Acting ◽  
Serum Tsh ◽  
Tsh Levels

Abstract. In the first part of this study, we have demonstrated that, in 7 patients with untreated thyrotoxicosis, a 7 day regime of the long acting dopamine antagonist metoclopramide (10 mg orally 8 hourly) produces more adequate dopaminergic blockade at pituitary level than a single oral 10 mg dose of the compound as assessed by serum prolactin responses. Subsequently, we have employed this protracted oral metoclopramide regime to evaluate the contribution of dopaminergic tone to the abnormal TSH and prolactin responsiveness of thyrotoxicosis. Serum TSH and prolactin responses to iv TRH (200 μg) were measured in 10 untreated thyrotoxic patients before and after a 7 day period of metoclopramide 10 mg orally 8 hourly. Ten euthyroid individuals were studied in similar fashion, their serum samples being analysed for prolactin levels alone, thus providing a control group for prolactin responsiveness to TRH, before and after metoclopramide. In the thyrotoxic patients basal TSH levels did not change as a consequence of metoclopramide therapy and the TSH response to TRH remained flat. Basal prolactin levels were similar in thyrotoxic and euthyroid individuals and the increase in prolactin, seen in both groups after metoclopramide, was smaller in the thyrotoxic group than in the euthyroid group. Prolactin responsiveness to TRH was significantly impaired in the thyrotoxic subjects as compared to euthyroid subjects. After metoclopramide there was a significant decline in prolactin responsiveness in the euthyroid group, and a similar, though insignificant, trend in the thyrotoxic patients. We conclude that in thyrotoxicosis dopaminergic tone plays no major part in the suppression of TSH levels, nor in the impaired prolactin responsiveness to TRH.

Serum prolactin and thyrotrophin responses to thyrotrophin-releasing hormone at different times of the day in normal women

1981 ◽  
Vol 97 (1) ◽  
pp. 7-11 ◽  
Author(s):  
F. R. Pérez-López ◽  
G. Gómez ◽  
M. D. Abós
Keyword(s):  
Serum Prolactin ◽  
Thyrotrophin Releasing Hormone ◽  
Releasing Hormone ◽  
Before And After ◽  
The Mean ◽  
The Difference ◽  
Normal Women ◽  
Hormonal Release ◽  
Test Serum ◽  
Serum Tsh

Abstract. In order to determine whether or not the pituitary responsiveness to thyrotrophin-releasing hormone (TRH) changes during the nyctohemeral cycle, 10 healthy regularly cycling women were given 200 μg of TRH at 02.00 h, 10.00 h and 18.00 h with at least a 32 h interval between each test. Serum prolactin (Prl) and thyrotrophin (TSH) in 7 of the 10 women were measured serially before and after TRH administration. The mean basal Prl levels were significantly higher (P < 0.01) at 02.00 h than at 10.00 h and 18.00 h. The mean basal TSH levels were higher, although not significantly, at 02.00 h than at 10.00 h and 18.00 h. Although a higher TSH release occurred at 02.00 h than at 10.00 h and 18.00 h, the mean serum TSH and Prl peak responses to TRH were statistically similar in the three groups of tests. The integrated changes scores, calculated as the difference between the average post-TRH hormonal release and the average baseline levels, although higher in the 18.00 h test for Prl and the 02.00 h test for TSH, were not statistically different among the three tests.

Effects of a dopamine antagonist (metoclopramide) on the release of LH, FSH, TSH and PRL in normal women throughout the menstrual cycle

1990 ◽  
Vol 122 (2) ◽  
pp. 211-216 ◽  
Author(s):  
Katsuyoshi Seki ◽  
Ichiro Nagata
Keyword(s):  
Menstrual Cycle ◽  
Luteal Phase ◽  
Significant Rise ◽  
Dopamine Antagonist ◽  
Endogenous Dopamine ◽  
Serum Lh ◽  
Normal Menstrual Cycle ◽  
Early Follicular Phase ◽  
Adenohypophyseal Hormones ◽  
Normal Women

Abstract To obtain further insight into the role of endogenous dopamine on the adenohypophyseal hormones secretion in normal women, responses of the adenohypophyseal hormones to a dopamine antagonist, metoclopramide, were evaluated in 7 normal women during the early follicular, late follicular and mid-luteal phases of the menstrual cycle. PRL increments following metoclopramide were similar in all phases. During the early and late follicular phases, metoclopramide induced no significant change in circulating LH levels. However, a significant rise in serum LH was observed following metoclopramide during the mid-luteal phase. No significant changes in serum FSH levels were observed after metoclopramide during any of the 3 phases of the cycle. Following metolopramide, serum TSH levels significantly rose in all phases. TSH increments following metoclopramide were significantly lower in the mid-luteal phase than in the early follicular phase. These results suggest that the modulatory effect of endogenous dopamine on adenohypophyseal hormones secretion is variable and selective throughout the normal menstrual cycle.

scholarly journals Twice-Daily Subcutaneous Injection of Kisspeptin-54 Does Not Abolish Menstrual Cyclicity in Healthy Female Volunteers

2013 ◽  
Vol 98 (11) ◽  
pp. 4464-4474 ◽  
Author(s):  
C. N. Jayasena ◽  
A. N. Comninos ◽  
G. M. K. Nijher ◽  
A. Abbara ◽  
A. De Silva ◽  
...  
Keyword(s):  
Menstrual Cycle ◽  
Reproductive Function ◽  
Reproductive Hormones ◽  
Follicular Phase ◽  
Hypothalamic Amenorrhea ◽  
Healthy Women ◽  
Lh Pulsatility ◽  
Serum Lh ◽  
Healthy Female ◽  
Ultrasound Parameters

Background: Kisspeptin is a critical hypothalamic regulator of reproductive function. Chronic kisspeptin administration causes profound tachyphylaxis in male monkeys and in women with functional hypothalamic amenorrhea. The pharmacological effects of chronic kisspeptin exposure in healthy women with normal menstrual cycles have not been studied previously. Aim: Our aim was to determine the effects of follicular-phase kisspeptin-54 treatment on menstrual cyclicity in healthy women. Methods: We performed a prospective, single-blinded, 1-way crossover study. Healthy women received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline during menstrual days 7–14 (n = 5 per treatment arm). Serial assessments of basal reproductive hormones, ultrasound parameters, LH pulsatility, and acute sensitivity to GnRH and kisspeptin-54 injection were performed. Results: Menstrual cyclicity persisted in all women after follicular-phase kisspeptin-54 treatment. Chronic exposure to kisspeptin-54 did not abolish acute stimulation of LH after injection of kisspeptin-54 or GnRH. In addition, kisspeptin-54 treatment was associated with a shorter mean length of the menstrual cycle (mean length of menstrual cycle was 28.6 ± 1.4 days with saline vs 26.8 ± 3.1 days with kisspeptin, P &lt; .01), earlier onset of highest recorded serum LH (mean menstrual day of highest LH was 15.2 ± 1.3 with saline vs 13.0 ± 1.9 with kisspeptin, P &lt; .05), and earlier onset of the luteal phase (mean menstrual day of progesterone increase was 18.0 ± 2.1 with saline vs 15.8 ± 0.9 with kisspeptin, P &lt; .05). Conclusion: Our data suggest that 1 week of exogenous kisspeptin-54 does not abolish menstrual cyclicity in healthy women. Further work is needed to determine whether kisspeptin could be used to treat certain anovulatory disorders.

RESTORATION OF OESTROGEN POSITIVE FEEDBACK EFFECT ON LH RELEASE BY BROMOCRIPTINE IN HYPERPROLACTINAEMIC PATIENTS WITH GALACTORRHOEA-AMENORRHOEA

1979 ◽  
Vol 91 (3) ◽  
pp. 591-600 ◽  
Author(s):  
Toshihiro Aono ◽  
Akira Miyake ◽  
Takenori Shioji Motoi Yasuda ◽  
Koji Koike ◽  
Keiichi Kurachi
Keyword(s):  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Serum Prolactin ◽  
Serum Luteinizing Hormone ◽  
Serum Lh ◽  
Lh Release ◽  
The Mean ◽  
Lh Rh ◽  
Lh Releasing Hormone ◽  
Positive Feedback Effect

ABSTRACT Five mg of bromocriptine was administered for 3 weeks to 8 hyperprolactinaemic women with galactorrhoea-amernorrhoea, in whom the response of serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to 100 μg of iv LH-releasing hormone (LH-RH) had been evaluated. Twenty mg of conjugated oestrogen (Premarin®) was injected iv any day between the 10th and 12th day from the initiation of the treatment, and serum LH levels were serially determined for 120 h. Hyperresponse of LH with normal FSH response to LH-RH was observed in most patients. Bromocriptine treatment for 10 to 12 days significantly suppressed mean (± se) serum prolactin (PRL) levels from 65.1 ± 23.0 to 10.4 ± 2.0 ng/ml, while LH (12.6 ± 2.1 to 24.8 ± 5.9 mIU/ml) and oestradiol (40.1 ± 7.6 to 111.4 ± 20.8 pg/ml) levels increased significantly. Patients on bromocriptine treatment showed LH release with a peak at 48 h after the injection of Premarin. The mean per cent increases in LH were significantly higher than those in untreated patients with galactorrhoea-amenorrhoea between 32 and 96 h after the injection. The present results seem to suggest that the restoration of LH-releasing response to oestrogen following suppression of PRL by bromocriptine may play an important role in induction of ovulation in hyperprolactinaemic patients with galactorrhoea-amenorrhoea.

scholarly journals A Clinico-etiological Evaluation of Hirsutism Patients: A Case Series

2021 ◽  
pp. 384-389
Author(s):  
Sohan A. Patel ◽  
Jayant B. Dave ◽  
Timir Y Mehta
Keyword(s):  
Hair Growth ◽  
Negative Impact ◽  
Serum Insulin ◽  
Case Series ◽  
Serum Testosterone ◽  
Serum Cortisol ◽  
Serum Prolactin ◽  
Ultrasound Study ◽  
Hormonal Evaluation ◽  
Serum Tsh

Background: Hirsutism is a condition of excess hair growth in females in male-like distribution. It is seen in almost 5-10% of women. Women having hirsutism have a negative impact on quality of life. Aim: All patients were subjected to ultrasound imaging (Sonography) and hormonal evaluation to establish possible causative factors. Methods: A prospective and retrospective study of hirsutism patients, who were evaluated at Samarpan medical research organization, Modasa, Gujarat from 2016 to 2019. Results: In this case series age and clinical presentation were studied in five female patients diagnosed with hirsutism. The patients age ranged from 16 to 22 years with a mean of 19.60 years. All these patients showed localized hair growth on the upper lip, chin, and cheek on the face. Ultrasound study revealed that one of the five patients had a right bulky ovary and four patients showed both ovaries with multiple follicles. In hormonal evaluation, in one of the three patients the LH: FSH ratio was found to be more than 3. Three out of the five patients showed elevated levels of 17-OHP and serum testosterone. Two out of the three patients showed an elevated level of serum insulin. The level of DHEAS, serum prolactin, serum cortisol, and serum TSH were found to be in a normal range. Conclusion: Ultrasonographic (USG) study revealed a positive correlation between PCOS and Hirsutism patients. Hirsutism patients were found to have higher levels of 17-OHP, serum testosterone, serum insulin, and a higher ratio of LH: FSH, one or more at a time suggesting a strong correlation between elevated levels of these hormones and hirsutism. The present study could not establish any meaningful correlation between the level of DHEAS, serum prolactin, serum cortisol, and serum TSH.

scholarly journals Correlation of Serum Prolactin and Thyroid Hormone in Female Infertility

2019 ◽  
Vol 17 (2) ◽  
pp. 32-34
Author(s):  
Fahat Banu
Keyword(s):  
Thyroid Hormone ◽  
Thyroid Dysfunction ◽  
Female Infertility ◽  
Serum Prolactin ◽  
Psychological Consequences ◽  
Medical College ◽  
Hormone Profile ◽  
Hormonal Imbalance ◽  
High Incidence ◽  
Serum Tsh

Background: Infertility is a growing problem with adverse medical, social and psychological consequences globally. Apart from several causes of infertility, hormonal imbalance especially thyroid dysfunction and hyperprolactinemia can lead to female infertility. Both these conditions are treatable so Proper management of hormonal imbalance can result in restoration of normal fertility. Aims and objectives: Correlation of serum Prolactin and Thyroid hormone in female infertility. Materials and methods: Descriptive hospital based study was conducted at Nepalgunj medical college and teaching hospital, Nepalgunj, Banke, Nepal. The data was collected from September 2018 to August 2019. Total 30 cases of females of primary and secondary infertility attending outpatient department of gynecology department of Nepalgunj medical college were included in the study. A detailed history and clinical evaluation was done along with estimation of serum Prolactin and Thyroid hormone profile. Result: Hormonal status of subjects showed 15 i.e. 50% participants were thyroid whereas 11 (36.33%) were hypothyroid and 4 (13.33%) were hyperthyroid. Serum Prolactin was raised in 17 (57%) and normal in 13 (43%). Serum TSH and prolactin were found to be significantly positively correlated in female infertility (r=0.507, p =0.004). Conclusion: There is a high incidence of hyperprolactinaemia and thyroid dysfunction in female infertility.

scholarly journals Hypothyroidism and hyperprolactinemia in women with primary and secondary infertility

2020 ◽  
Vol 14 (1) ◽  
pp. 41-46
Author(s):  
Shamima Bari ◽  
Rokeya Begum ◽  
Qazi Shamima Akter
Keyword(s):  
Thyroid Stimulating Hormone ◽  
Serum Prolactin ◽  
Enzyme Linked Immunosorbent Assay ◽  
Secondary Infertility ◽  
Overnight Fasting ◽  
The Mean ◽  
Altered Thyroid ◽  
Serum Thyroid Hormones ◽  
Serum Tsh ◽  
Fertile Women

Background and objectives: Infertility is a global health problem including Bangladesh. Altered thyroid and prolactin levels have been implicated as a cause of infertility. The study was undertaken to find out the serum thyroid hormones and prolactin status in women with primary and secondary infertility. Methods: Women with primary and secondary infertility were enrolled. Fertile age-matched women were included as control. The anthropometric details (age, height and weight) were recorded. Overnight fasting blood sample was collected on 2nd day of menstrual cycle of the follicular phase. Serum thyroid stimulating hormone (TSH), free tri-iodothyronine (FT3) and free thyroxine (FT4) were measured by enzyme-linked immunosorbent assay (ELISA). Serum prolactin (PRL) was estimated by radioimmunoassay. Results: A total of 150 women were enrolled in the study. Out of 150 women, 50 had primary and 50 had secondary infertility while 50 women were age-matched fertile women as control. The mean TSH levels of both infertility groups were significantly higher than that of fertile women. Regarding thyroid function, 24% and 28% of women with primary and secondary infertility had hypothyroidism respectively. The serum prolactin level was high in 42.9% and 50% of hypothyroid cases in primary and secondary infertility groups respectively. Conclusion: The study has demonstrated high occurrence of hypothyroidism with raised serum prolactin levels among infertile females emphasizing the importance of estimating both serum TSH and prolactin in infertility. Ibrahim Med. Coll. J. 2020; 14(1): 41-46

Sign in / Sign up

Export Citation Format

Share Document